$MEDP

Carley Brian T sold $3.0M of MEDP

Carley Brian T sold 5,000 shares of Medpace Holdings, Inc. (MEDP) at $608.63 ($3.04M total) on 2026-08-19.

Original reporting
SEC EDGAR · Carley Brian T
Published Aug 21, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MEDP
Bearish
medium confidence
Mentioned
$MEDP
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishLow
01

Why it matters

The disclosed sale provides fresh data for traders assessing insider sentiment.

02

Market read

Insider sales can influence short-term price movement; traders may watch MEDP for volatility.

03

What to watch

No accompanying corporate news; the director may be diversifying assets.

Relevance 6/10Novelty 6/10Timing: filed today

Background

Form 4 filings disclose insider transactions; a director's sale is publicly reported.

Company-level read

Ticker impact

$MEDPBearishMedium confidence
Context

Director Carley Brian T sold 5,000 shares for $3.04M, reducing his stake to 27,825 shares.

Expected impact

Possible modest downside of 2-4% over the next few days.

Evidence & confidence

A $3M insider sale by a director is material but not unusually large; market may react cautiously.

Market effects

Minimal impact on the broader healthcare services sector.

Limited to U.S. markets where MEDP trades.

Low

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Medpace Holdings, Inc.

    Clinical research organization listed on NASDAQ.

  • Carley Brian T

    Director of Medpace who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.